The mevalonate pathway in C. Elegans

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Rauthan, Manish ^a   Pilon, Marc ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

C. elegans; cholesterol; coenzyme Q; dolichol; mevalonate pathway; protein prenylation; statin

Indexed keywords

ADENOSINE DERIVATIVE; CHOLESTEROL; DOLICHOL; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPENTENYL DIPHOSPHATE; ISOPENTYL ADENOSINE; MEVALONIC ACID; MITOCHONDRIAL DNA; NUCLEOTIDE; PROTEIN FARNESYLTRANSFERASE; STEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN; UBIQUINONE; UNCLASSIFIED DRUG; CAENORHABDITIS ELEGANS PROTEIN;

BACTERIAL SURVIVAL; BIOSYNTHESIS; CAENORHABDITIS ELEGANS; CHEMICAL MODIFICATION; CHOLESTEROL SYNTHESIS; ELECTRON TRANSPORT; EMBRYO DEVELOPMENT; ENZYME SYNTHESIS; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; HEART FUNCTION; HOMEOSTASIS; HUMAN; LETHALITY; LONGEVITY; NONHUMAN; PROTEIN BINDING; PROTEIN GLYCOSYLATION; PROTEIN PRENYLATION; REVIEW; RNA TRANSLATION; WORM; ANIMAL; ENZYMOLOGY; GENETICS; GLYCOSYLATION; KINETICS; METABOLISM; PROTEIN PROCESSING;

CAENORHABDITIS ELEGANS;

ANIMALS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; GLYCOSYLATION; HUMANS; KINETICS; METABOLIC NETWORKS AND PATHWAYS; MEVALONIC ACID; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUINONE;

EID: 84455193298     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-243     Document Type: Review

References (89)

1. Coenzyme Q - biosynthesis and functions. Bentinger M, Tekle M, Dallner G, Biochemical and biophysical research communications 2010 396 74 79 10.1016/j.bbrc.2010.02.147 20494114
2. Statins and cancer prevention. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM, Nat Rev Cancer 2005 5 930 942 10.1038/nrc1751 16341084 (Pubitemid 41766782)
3. Overcoming multidrug-resistance in cancer: statins offer a logical candidate. Mehta NG, Mehta M, Medical hypotheses 2010 74 237 239 10.1016/j.mehy.2009.09.039 19879695
4. The use of statins in hematopoietic stem cell transplantation. Shimabukuro-Vornhagen A, Glossmann J, Liebig T, Scheid C, von Bergwelt-Baildon M, Current stem cell research & therapy 2009 4 260 265 10.2174/ 157488809789649250 22202004
5. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Willey JZ, Elkind MS, Archives of neurology 2010 67 1062 1067 10.1001/archneurol.2010.199 20837848
6. Statins inhibit protein lipidation and induce the unfolded protein response in the non-sterol producing nematode Caenorhabditis elegans. Morck C, Olsen L, Kurth C, Persson A, Storm NJ, Svensson E, Jansson JO, Hellqvist M, Enejder A, Faergeman NJ, Pilon M, Proc Natl Acad Sci USA 2009 106 18285 18290 10.1073/pnas.0907117106 19826081
7. Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Miziorko HM, Archives of biochemistry and biophysics 2011 505 131 143 10.1016/j.abb.2010.09.028 20932952
8. Isopentenyl-diphosphate isomerase is essential for viability of Caenorhabditis elegans. Yochem J, Hall DH, Bell LR, Hedgecock EM, Herman RK, Molecular genetics and genomics: MGG 2005 273 158 166 10.1007/s00438-004-1101-x 15765206 (Pubitemid 40674715)
9. Synthesis and function of isopentenyl adenosine derivatives in tRNA. Persson BC, Esberg B, Olafsson O, Bjork GR, Biochimie 1994 76 1152 1160 10.1016/0300-9084(94)90044-2 7748950
10. Translational operator of mRNA on the ribosome: how repressor proteins exclude ribosome binding. Jenner L, Romby P, Rees B, Schulze-Briese C, Springer M, Ehresmann C, Ehresmann B, Moras D, Yusupova G, Yusupov M, Science 2005 308 120 123 10.1126/science.1105639 15802605 (Pubitemid 40471012)
11. Regulation of physiological rates in Caenorhabditis elegans by a tRNA-modifying enzyme in the mitochondria. Lemieux J, Lakowski B, Webb A, Meng Y, Ubach A, Bussiere F, Barnes T, Hekimi S, Genetics 2001 159 147 157 11560893 (Pubitemid 32917366)
12. Defects in tRNA modification associated with neurological and developmental dysfunctions in Caenorhabditis elegans elongator mutants. Chen C, Tuck S, Bystrom AS, PLoS genetics 2009 5 1000561 10.1371/journal.pgen.1000561 19593383
13. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Ashton E, Windebank E, Skiba M, Reid C, Schneider H, Rosenfeldt F, Tonkin A, Krum H, International journal of cardiology 2011 146 404 407 10.1016/j.ijcard.2009.12.028 20085851
14. Lovastatin decreases coenzyme Q levels in humans. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H, Proceedings of the National Academy of Sciences of the United States of America 1990 87 8931 8934 10.1073/pnas.87.22.8931 2247468 (Pubitemid 120007623)
15. Ubiquinone is necessary for Caenorhabditis elegans development at mitochondrial and non-mitochondrial sites. Hihi AK, Gao Y, Hekimi S, The Journal of biological chemistry 2002 277 2202 2206 10.1074/jbc.M109034200 11706003 (Pubitemid 34968807)
16. A dietary source of coenzyme Q is essential for growth of long-lived Caenorhabditis elegans clk-1 mutants. Jonassen T, Larsen PL, Clarke CF, Proceedings of the National Academy of Sciences of the United States of America 2001 98 421 426 10.1073/pnas.021337498 11136229 (Pubitemid 32105056)
17. Structural and functional conservation of the Caenorhabditis elegans timing gene clk-1. Ewbank JJ, Barnes TM, Lakowski B, Lussier M, Bussey H, Hekimi S, Science 1997 275 980 983 10.1126/science.275.5302.980 9020081 (Pubitemid 27087714)
18. Silencing of ubiquinone biosynthesis genes extends life span in Caenorhabditis elegans. Asencio C, Rodriguez-Aguilera JC, Ruiz-Ferrer M, Vela J, Navas P, The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2003 17 1135 1137
19. C. elegans knockouts in ubiquinone biosynthesis genes result in different phenotypes during larval development. Gavilan A, Asencio C, Cabello J, Rodriguez-Aguilera JC, Schnabel R, Navas P, BioFactors 2005 25 21 29 10.1002/biof.5520250104 16873927 (Pubitemid 44070830)
20. A regulated response to impaired respiration slows behavioral rates and increases lifespan in Caenorhabditis elegans. Cristina D, Cary M, Lunceford A, Clarke C, Kenyon C, PLoS genetics 2009 5 1000450 10.1371/journal.pgen.1000450 19360127
21. Interorganelle signaling is a determinant of longevity in Saccharomyces cerevisiae. Kirchman PA, Kim S, Lai CY, Jazwinski SM, Genetics 1999 152 179 190 10224252 (Pubitemid 29222525)
22. Coenzyme Q supports distinct developmental processes in Caenorhabditis elegans. Asencio C, Navas P, Cabello J, Schnabel R, Cypser JR, Johnson TE, Rodriguez-Aguilera JC, Mechanisms of ageing and development 2009 130 145 153 10.1016/j.mad.2008.10.004 19007804
23. Polyisoprenoids-Secondary metabolites or physiologically important superlipids? Surmacz L, Swiezewska E, Biochemical and biophysical research communications 2011 407 627 632 10.1016/j.bbrc.2011.03.059 21419101
24. Polyisoprenoid alcohols - recent results of structural studies. Skorupinska-Tudek K, Wojcik J, Swiezewska E, Chemical record 2008 8 33 45 10.1002/tcr.20137 18302278
25. Polyisoprenoids: structure, biosynthesis and function. Swiezewska E, Danikiewicz W, Progress in lipid research 2005 44 235 258 10.1016/j.plipres. 2005.05.002 16019076 (Pubitemid 40968039)
26. Biosynthesis of N-acetylglucosamine-P-P-dolichol, the committed step of asparagine-linked oligosaccharide assembly. Lehrman MA, Glycobiology 1991 1 553 562 10.1093/glycob/1.6.553 1668306
27. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E, et al. Cell 2010 142 203 217 10.1016/j.cell.2010.06.001 20637498
28. Hypoglycosylation due to dolichol metabolism defects. Denecke J, Kranz C, Biochimica et biophysica acta 2009 1792 888 895 19419701
29. Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Haeuptle MA, Hennet T, Human mutation 2009 30 1628 1641 10.1002/humu.21126 19862844
30. Congenital disorders of glycosylation: a booming chapter of pediatrics. Jaeken J, Carchon H, Current opinion in pediatrics 2004 16 434 439 10.1097/01.mop.0000133636.56790.4a 15273506 (Pubitemid 39006493)
31. Proteomics reveals N-linked glycoprotein diversity in Caenorhabditis elegans and suggests an atypical translocation mechanism for integral membrane proteins. Kaji H, Kamiie J, Kawakami H, Kido K, Yamauchi Y, Shinkawa T, Taoka M, Takahashi N, Isobe T, Molecular & cellular proteomics: MCP 2007 6 2100 2109 10.1074/mcp.M600392-MCP200 22211244
32. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, Gotta M, Kanapin A, Le Bot N, Moreno S, Sohrmann M, et al. Nature 2003 421 231 237 10.1038/nature01278 12529635 (Pubitemid 36139121)
33. Genome-wide RNAi of C. elegans using the hypersensitive rrf-3 strain reveals novel gene functions. Simmer F, Moorman C, van der Linden AM, Kuijk E, van den Berghe PVE, Kamath RS, Fraser AG, Ahringer J, Plasterk RHA, PloS Biol 2003 1 12 14551910
34. Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Sonnichsen B, Koski LB, Walsh A, Marschall P, Neumann B, Brehm M, Alleaume AM, Artelt J, Bettencourt P, Cassin E, et al. Nature 2005 434 462 469 10.1038/nature03353 15791247 (Pubitemid 40477050)
35. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG, Nat Rev Drug Discov 2007 6 541 555 10.1038/nrd2221 17585331 (Pubitemid 47019443)
36. Isoprenylation of polypeptides in the nematode Caenorhabditis elegans. Aspbury RA, Prescott MC, Fisher MJ, Rees HH, Biochim Biophys Acta 1998 1392 265 275 9630668 (Pubitemid 28287329)
37. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Hara M, Han M, Proceedings of the National Academy of Sciences of the United States of America 1995 92 3333 3337 10.1073/pnas.92.8.3333 7536929
38. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells. Nagase T, Kawata S, Tamura S, Matsuda Y, Inui Y, Yamasaki E, Ishiguro H, Ito T, Miyagawa J, Mitsui H, et al. British journal of cancer 1997 76 1001 1010 10.1038/bjc.1997.499 9376258 (Pubitemid 27434655)
39. Targeting the mevalonate pathway in multiple myeloma. van der Spek E, Leukemia research 2010 34 267 268 10.1016/j.leukres.2009.07.027 19695704
40. Reversal of age-dependent nuclear morphology by inhibition of prenylation does not affect lifespan in Caenorhabditis elegans. Bar DZ, Gruenbaum Y, Nucleus 2010 1 499 505 21327093
41. Sterol requirement for reproduction of a free-living nematode. Hieb WF, Rothstein M, Science 1968 160 778 780 10.1126/science.160.3829.778 4869093
42. The sterol modifying enzyme LET-767 is essential for growth, reproduction and development in Caenorhabditis elegans. Kuervers LM, Jones CL, O'Neil NJ, Baillie DL, Molecular genetics and genomics: MGG 2003 270 121 131 10.1007/s00438-003-0900-9 12905072 (Pubitemid 37452507)
43. Sterol-derived hormone(s) controls entry into diapause in Caenorhabditis elegans by consecutive activation of DAF-12 and DAF-16. Matyash V, Entchev EV, Mende F, Wilsch-Brauninger M, Thiele C, Schmidt AW, Knolker HJ, Ward S, Kurzchalia TV, PLoS biology 2004 2 280 10.1371/journal.pbio.0020280 15383841 (Pubitemid 39532917)
44. Role of cholesterol in germ-line development of Caenorhabditis elegans. Shim YH, Chun JH, Lee EY, Paik YK, Molecular reproduction and development 2002 61 358 366 10.1002/mrd.10099 11835581 (Pubitemid 34117053)
45. Long-term effects of sterol depletion in C. elegans: sterol content of synchronized wild-type and mutant populations. Merris M, Kraeft J, Tint GS, Lenard J, Journal of lipid research 2004 45 2044 2051 10.1194/jlr.M400100-JLR200 15314097 (Pubitemid 40990899)
46. Sterol effects and sites of sterol accumulation in Caenorhabditis elegans: developmental requirement for 4alpha-methyl sterols. Merris M, Wadsworth WG, Khamrai U, Bittman R, Chitwood DJ, Lenard J, Journal of lipid research 2003 44 172 181 10.1194/jlr.M200323-JLR200 12518036 (Pubitemid 36114783)
47. Receptor-mediated endocytosis in the Caenorhabditis elegans oocyte. Grant B, Hirsh D, Molecular biology of the cell 1999 10 4311 4326 10588660
48. Tissue-specific synthesis of yolk proteins in Caenorhabditis elegans. Kimble J, Sharrock WJ, Developmental biology 1983 96 189 196 10.1016/0012-1606(83)90322-6 6825952
49. Distribution and transport of cholesterol in Caenorhabditis elegans. Matyash V, Geier C, Henske A, Mukherjee S, Hirsh D, Thiele C, Grant B, Maxfield FR, Kurzchalia TV, Molecular biology of the cell 2001 12 1725 1736 11408580 (Pubitemid 33049725)
50. Multicolor bleach-rate imaging enlightens in vivo sterol transport. Wustner D, Sage D, Communicative & integrative biology 2010 3 370 373 10.4161/cib.3.4.11972 22211217
51. Sterol metabolism in the nematodeCaenorhabditis elegans. Chitwood DJ, Lusby WR, Lozano R, Thompson MJ, Svoboda JA, Lipids 1984 19 500 506 10.1007/BF02534482 21344279
52. Involvement of caveolin-1 in meiotic cell-cycle progression in Caenorhabditis elegans. Scheel J, Srinivasan J, Honnert U, Henske A, Kurzchalia TV, Nature cell biology 1999 1 127 129 10.1038/10100 10559886 (Pubitemid 129501956)
53. A gp330/megalin-related protein is required in the major epidermis of Caenorhabditis elegans for completion of molting. Yochem J, Tuck S, Greenwald I, Han M, Development 1999 126 597 606 9876188 (Pubitemid 29082046)
54. Hormonal signals produced by DAF-9/cytochrome P450 regulate C. elegans dauer diapause in response to environmental cues. Gerisch B, Antebi A, Development 2004 131 1765 1776 10.1242/dev.01068 15084461 (Pubitemid 38559844)
55. A hormonal signaling pathway influencing C. elegans metabolism, reproductive development, and life span. Gerisch B, Weitzel C, Kober-Eisermann C, Rottiers V, Antebi A, Developmental cell 2001 1 841 851 10.1016/S1534- 5807(01)00085-5 11740945 (Pubitemid 33586137)
56. A circulatory transcriptional regulation among daf-9, daf-12, and daf-16 mediates larval development upon cholesterol starvation in Caenorhabditis elegans. Jeong MH, Kawasaki I, Shim YH, Developmental dynamics: an official publication of the American Association of Anatomists 2010 239 1931 1940 10.1002/dvdy.22322
57. Synthesis and activity of dafachronic acid ligands for the C. elegans DAF-12 nuclear hormone receptor. Sharma KK, Wang Z, Motola DL, Cummins CL, Mangelsdorf DJ, Auchus RJ, Molecular endocrinology 2009 23 640 648 10.1210/me.2008-0415 19196833
58. NCR-1 and NCR-2, the C. elegans homologs of the human Niemann-Pick type C1 disease protein, function upstream of DAF-9 in the dauer formation pathways. Li J, Brown G, Ailion M, Lee S, Thomas JH, Development 2004 131 5741 5752 10.1242/dev.01408 15509773 (Pubitemid 39625216)
59. Regulation of the mevalonate pathway. Goldstein JL, Brown MS, Nature 1990 343 425 430 10.1038/343425a0 1967820 (Pubitemid 20065229)
60. Protein sensors for membrane sterols. Goldstein JL, DeBose-Boyd RA, Brown MS, Cell 2006 124 35 46 10.1016/j.cell.2005.12.022 16413480 (Pubitemid 43069308)
61. Regulation of sterol synthesis in eukaryotes. Espenshade PJ, Hughes AL, Annual review of genetics 2007 41 401 427 10.1146/annurev.genet.41.110306.130315 17666007
62. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap inaccessible to COPII proteins. Sun LP, Seemann J, Goldstein JL, Brown MS, Proceedings of the National Academy of Sciences of the United States of America 2007 104 6519 6526 10.1073/pnas. 0700907104 17428919 (Pubitemid 47175534)
63. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, Goldstein JL, Brown MS, Cell 2002 110 489 500 10.1016/S0092-8674(02)00872-3 12202038 (Pubitemid 35232292)
64. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Correll CC, Ng L, Edwards PA, The Journal of biological chemistry 1994 269 17390 17393 8021239
65. Control of cholesterol synthesis through regulated ER-associated degradation of HMG CoA reductase. Jo Y, Debose-Boyd RA, Critical reviews in biochemistry and molecular biology 2010 45 185 198 10.3109/10409238.2010.485605 20482385
66. Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Meigs TE, Simoni RD, Archives of biochemistry and biophysics 1997 345 1 9 10.1006/abbi.1997.0200 9281305 (Pubitemid 27374202)
67. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. Nakanishi M, Goldstein JL, Brown MS, The Journal of biological chemistry 1988 263 8929 8937 3379053
68. C elegans: a model for exploring the genetics of fat storage. McKay RM, McKay JP, Avery L, Graff JM, Dev Cell 2003 4 131 142 10.1016/S1534-5807(02) 00411-2 12530969 (Pubitemid 36105339)
69. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkun G, Nature 2003 421 268 272 10.1038/nature01279 12529643 (Pubitemid 36139130)
70. An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Yang F, Vought BW, Satterlee JS, Walker AK, Jim Sun ZY, Watts JL, DeBeaumont R, Saito RM, Hyberts SG, Yang S, et al. Nature 2006 442 700 704 10.1038/nature04942 16799563 (Pubitemid 44215326)
71. Post-prenylation-processing enzymes as new targets in oncogenesis. Winter-Vann AM, Casey PJ, Nature reviews Cancer 2005 5 405 412 10.1038/nrc1612 15864282 (Pubitemid 40637832)
72. Isoprenoids as mediators of the biological effects of statins. Liao JK, The Journal of clinical investigation 2002 110 285 288 12163444 (Pubitemid 34847957)
73. Pleiotropic effects of statins.-Basic research and clinical perspectives. Zhou Q, Liao JK, Circulation journal: official journal of the Japanese Circulation Society 2010 74 818 826 10.1253/circj.CJ-10-0110
74. Role of Rho GTPases and their regulators in cancer progression. Rathinam R, Berrier A, Alahari SK, Frontiers in bioscience: a journal and virtual library 2011 17 2561 2571
75. Mechanisms for the anti-inflammatory effects of statins. Bu DX, Griffin G, Lichtman AH, Current opinion in lipidology 2011 22 165 170 10.1097/MOL.0b013e3283453e41 21412153
76. Statins exhibit anticancer effects through modifications of the pAkt. Miraglia E, Hogberg J, Stenius U, International journal of oncology 2011 40 867 875
77. Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. Parvathy S, Ehrlich M, Pedrini S, Diaz N, Refolo L, Buxbaum JD, Bogush A, Petanceska S, Gandy S, Journal of neurochemistry 2004 90 1005 1010 10.1111/j.1471-4159.2004.02521.x 15287907 (Pubitemid 39099983)
78. Alzheimer disease: Statins in the treatment of Alzheimer disease. Sparks DL, Nature reviews Neurology 2011 7 662 663
79. Statin Myopathy: A Lipid Clinic Experience on the Tolerability of Statin Rechallenge. Fung EC, Crook MA, Cardiovascular therapeutics 2011
80. Expression, purification, and characterization of the human squalene synthase: use of yeast and baculoviral systems. Soltis DA, McMahon G, Caplan SL, Dudas DA, Chamberlin HA, Vattay A, Dottavio D, Rucker ML, Engstrom RG, Cornell-Kennon SA, et al. Archives of biochemistry and biophysics 1995 316 713 723 10.1006/abbi.1995.1095 7864626
81. Purification and properties of geranylgeranyl-diphosphate synthase from bovine brain. Sagami H, Morita Y, Ogura K, The Journal of biological chemistry 1994 269 20561 20566 8051156 (Pubitemid 24260465)
82. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. Brown MS, Goldstein JL, Journal of lipid research 1980 21 505 517 6995544 (Pubitemid 11194847)
83. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Furfine ES, Leban JJ, Landavazo A, Moomaw JF, Casey PJ, Biochemistry 1995 34 6857 6862 10.1021/bi00020a032 7756316
84. Human cytoplasmic 3-hydroxy-3-methylglutaryl coenzyme A synthase: expression, purification, and characterization of recombinant wild-type and Cys129 mutant enzymes. Rokosz LL, Boulton DA, Butkiewicz EA, Sanyal G, Cueto MA, Lachance PA, Hermes JD, Archives of biochemistry and biophysics 1994 312 1 13 10.1006/abbi.1994.1273 7913309
85. Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Qiu Y, Li D, Organic letters 2006 8 1013 1016 10.1021/ol052573s 16524256 (Pubitemid 43690648)
86. Inhibition of cholesterol biosynthesis by fluorinated mevalonate analogues. Reardon JE, Abeles RH, Biochemistry 1987 26 4717 4722 10.1021/bi00389a018 3663621 (Pubitemid 17129297)
87. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G, Archives of biochemistry and biophysics 2000 373 231 241 10.1006/abbi.1999.1502 10620343 (Pubitemid 30046509)
88. Biochemical and molecular mechanisms of action of bisphosphonates. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J, Bone 2011 49 34 41 10.1016/j.bone.2010. 11.008 21111853
89. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Wiemer AJ, Tong H, Swanson KM, Hohl RJ, Biochemical and biophysical research communications 2007 353 921 925 10.1016/j.bbrc.2006.12.094 17208200 (Pubitemid 46080385)